Search This Blog

Saturday, July 17, 2021

LA County Sheriff Says He Will Not Enforce New Indoor Mask Mandate

 By Mimi Nguyen Ly via The Epoch Times,

Los Angeles County Sheriff Alex Villanueva announced Friday that he will not enforce a new indoor mask mandate set to be reinstated in the country’s most populous county amid the CCP virus pandemic.


County health officials decided that the indoor mask mandate would apply regardless of a person’s vaccination status. The mandate, announced on Thursday, takes effect at 11:59 p.m. on Saturday.

“Forcing the vaccinated and those who already contracted COVID-19 to wear masks indoors is not backed by science and contradicts the U.S. Centers for Disease Control and Prevention (CDC) guidelines,” Villanueva said in a statement.

“The Los Angeles County Department of Public Health (DPH) has authority to enforce the order, but the underfunded/defunded Los Angeles County Sheriff’s Department will not expend our limited resources and instead ask for voluntary compliance.

“We encourage the DPH to work collaboratively with the Board of Supervisors and law enforcement to establish mandates that are both achievable and supported by science.”

The CDC announced in May this year that people fully vaccinated against the CCP (Chinese Communist Party) virus, which causes the disease COVID-19, no longer have to wear masks indoors.

An updated guidance on the CDC website as of Friday reads,

“Fully vaccinated people can resume activities without wearing a mask or physically distancing, except where required by federal, state, local, tribal, or territorial laws, rules, and regulations, including local business and workplace guidance.”

The LA County Health Department said on Thursday that transmission of the CCP virus was increasing “from Moderate to Substantial,” citing the “trend in daily new cases of COVID-19.”

In a statement, the department said that it had observed a seven-times increase in new cases since California fully reopened its economy on June 15 by dropping all physical distancing requirements and capacity limits, and relaxed most of its mask requirements.

“Wearing a mask when indoors reduces the risk of both getting and transmitting the virus. This additional layer of protection can help to slow the spread and does not limit business occupancy and operations,” the department asserted.

LA County Health Officer Muntu Davis said the new mask mandate will remain in place “until we begin to see improvements in our community transmission of COVID-19.”

He adds that the health department urges all residents who are eligible to get vaccinated.

“Although not at 100 [percent], [getting vaccinated] significantly reduces the risk of infection and, for the small number of people that get infected, it reduces the risk of hospitalization and death once you are fully vaccinated against COVID-19,” Davis said.

The department said in its statement that it is “a great time” to plan on vaccinating children who are 12 and older, and pointed out that the Pfizer COVID-19 vaccine is approved for those aged 12 and older.

It announced incentives for receiving the vaccine, saying that starting Friday through July 22, people 18 and older can have a chance at winning grand prizes if they get vaccinated at county-run vaccination sites, LA City sites, and St. John’s Well Child and Family Center sites. There are seven packages of tickets to attend the Staples Center to certain performances, it announced.

Vaccine providers can report any serious adverse effects or vaccination administration errors to VAERS, hosted by the U.S. Department of Health and Human Services.

Vaccine manufacturers are immune from liability for any adverse reactions to their products unless there’s “willful misconduct” involved.

The federal government has a Countermeasures Injury Compensation Program that can pay compensation to eligible persons who suffer serious injury from approved vaccines. But the burden of proof has proven a challenging process.

https://www.zerohedge.com/covid-19/la-county-sheriff-says-he-will-not-enforce-new-indoor-mask-mandate

'This Is Reality' - NYC Is Reopening, But Businesses Aren't Coming Back

 Signs of an economic revival in Manhattan have been shattered by the sad reality that businesses aren't returning to the borough. Vacancies are piling up as rents plunge as the whole recovery narrative falls apart. 

According to the Real Estate Board of New York's spring 2021 retail market report, rents declined across Manhattan's prime-time retail shops, with one neighborhood in Lower Manhattan, called SoHo, down 37%. 

"Signs of a nascent recovery are tempered by the reality that traffic in most retail corridors is far from approaching pre-pandemic levels," the report said.

In April, while everyone championed the grand reopening of the city, we showed how rents in the borough continued to slide. As long as work-at-home continues to dominate, the recovery in Manhattan will remain subdued. 

It's one thing to explain the borough's economic demise in words, but viewing it through a series of videos is an entirely different level to gain the perspective that the city is in trouble. 

The collapse of asking rents for vacant retail spaces lining the sidewalks along the borough was documented this week by YouTuber "Louis Rossmann" who has 1.56 million subscribers. 

In two separate lengthy videos, Rossmann, in detail, walks around Midtown Manhattan and shows viewers dozens and dozens of vacant storefronts. 

In one of the videos titled "NYC's reopening, but businesses aren't coming back," he said you "can walk eight steps" down the street and find a vacant retail shop. 

"This is clearly not sustainable - at some point, this [NYC commercial real estate market] will crash - and what people will tell you is that it's impossible - there's no way it could crash," Rossmann said. He noted that some of these places were vacant even before COVID. 

He said, "there is a thing with commercial mortgage-backed securities where the building has a certain value and is based on the rent they can get - and the value of the building doesn't get officially marked down until the rent is lowered." 

We've been among some of the first to document credit risks in commercial real estate markets, everything from malls to office buildings to hotels. However, the Reserve Board backstopped the credit markets through an emergency lending program during the pandemic. Now with the program winding down, and the vacancies continue to pile up, issues in the industry still linger. 

In another video, Rossmann continues to document the urban decay spreading across the borough. He said businesses are simply not coming back. 

As of June, only 20.7% of employees in New York City were back in offices. Without workers in buildings, the recovery at retail shops will remain lackluster. 

We pointed out last year that NYC's downturn could last years... 

https://www.zerohedge.com/markets/reality-nycs-reopening-businesses-arent-coming-back

Facebook issues harsh response to Biden accusation the platform is 'killing people'

 Facebook is pushing back against the White House's narrative that the social media platform is "killing people."

"In private exchanges the Surgeon General has praised our work, including our efforts to inform people about COVID-19. They knew what they were doing. The White House is looking for scapegoats for missing their vaccine goals," a Facebook spokesperson told NBC's Dylan Beyers.

"The fact is that more than 2 billion people have viewed authoritative information about COVID-19 and vaccines on Facebook, which is more than any place on the internet," the spokesperson said. "More than 3.3 million Americans have also used our vaccine finder tool to find our where and how to get the vaccine. The facts show that Facebook is helping save lives. Period."

President Biden on Friday accused Facebook of "killing people" by way of misinformation on coronavirus vaccines being shared on the website, saying, "The only pandemic we have is among the unvaccinated, and they’re killing people."


The rebuttals come after Facebook press secretary Jen Psaki said Thursday that the Biden administration has been "flagging" content for Facebook to remove.

"We're flagging problematic posts for Facebook that spread disinformation. We're working with doctors and medical experts…who are popular with their audience with accurate information," she said. "So, we're helping get trusted content out there."

The Surgeon General's office issued a new report Wednesday titled, "Confronting Health Misinformation," that makes recommendations for social media platforms to "impose clear consequences for accounts that repeatedly violate platform policies."

Surgeon General Vivek Murthy during the Thursday briefing said misinformation is a public health threat.


"Surgeon General advisories are [usually] reserved for urgent public health threats," he said. "And while those threats have often been related to what we eat, drink, & smoke, today we live in a world where misinformation poses an imminent & insidious threat to our nation’s health."

Starting as early as January of 2020, Facebook's third-party fact-check team has been working with global health professionals to review and debunk false claims about the virus. The company lets users know when they have "liked" coronavirus hoaxes posted to the platform of more than 2 billion users, according to a blog post.

"We’ve removed more than 12 million pieces of content about COVID-19 and vaccines," a Facebook blog post from April 19 reads.


It also uses human moderators, as well as artificial intelligence (AI) tools, to remove or fact-check content related to COVID-19 and vaccines that may potentially harm users on the platform and on Instagram, according to its website. The company has worked with the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and other local health departments to share information about the pandemic.

Still, critics have accused the website of giving a platform to voices that question the vaccine or COVID-19 in general.

https://www.foxbusiness.com/politics/biden-facebook-killing-people-response

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

 Already facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Affinivax reported positive phase 2 results with its ASP3772 candidate – plus a new breakthrough designation from the FDA.

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.

The bulk of Prevnar 13 sales come from use in adults, and with Merck & Co in the final stages of regulatory review of its rival vaccine V114 – covering 15 serotypes and filed for adult use – the franchise is facing some serious competition for the first time.

Pfizer is fighting back with the approval of its new Prevnar 20 shot last month, covering 20 serotypes, but ASP3772 is attempting to go even further with coverage of 24 serotypes thanks to Affinivax’ multiple antigen presenting system, or MAPS.

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

There’s another key difference as well, according to the biotech, which is developing the new shot with big pharma partner Astellas under the terms of an agreement signed in 2017.

The MAP technology combines polysaccharide and protein antigens – joined with a biotin-rhizavidin bond – that can stimulate both B cell (antibody) and T cell immune responses with a single shot.

Conventional conjugate vaccines use covalent bonding to join the polysaccharide and protein antigens, which affects the way both are presented to the immune system.

The phase 2 trial involved more than 500 subjects aged 50 or over and showed that Affinivax was able to stimulate an antibody response to each of the 24 polysaccharides as well the conserved pneumococcal proteins.

The study also made a direct comparison with Prevnar 13, and found that for the 13 serotypes the two shots had in common, ASP3772 demonstrated a “similar or better” immune response measured by the level of antibody generation and their functional activity.

Affinivax’ shot performed better than Prevnar 13 against serotype 3 – arguably the most problematic variant in terms of clinical severity – at all doses, and against serotypes 5 and 19F at the highest dose.

ASP3772 was also pitted against the combination of Prevnar 13 and Merck’s older polysaccharide-based Pneumovax 23 vaccine. It achieved statistically higher immune responses for serotypes 3, 4, 5, 6A, 7F, 9V, and 18C at the highest dose tested, and at least similar – and in most cases statistically higher – for the remaining 11 serotypes.

“We believe that ASP3772 has the potential to offer broader protection than any pneumococcal vaccine currently on the market or in clinical testing today , and we look forward to continuing to advance this important vaccine candidate through clinical trials in both adults and infants,” said Affinivax’ chief executive Steve Brugger.

Preparation for a phase 3 programme is underway, and in the meantime the pneumococcal vaccine space looks set for a shake-up, as Pfizer tries to transition to Prevnar 20 and Merck tries to carve a slice of the market for V114.

Also emerging from the wings is Vaxcyte, which has a 24-valent shot in early development and hopes to have initial clinical data from that programme in late 2022/early 2023.

https://pharmaphorum.com/news/shot-in-the-arm-for-affinivax-as-it-challenges-pfizers-prevnar/

Covid leading cause of death for on-duty LEOs this year and 2020

 Search by Year

 

Total Line of Duty Deaths: 163





Primary healthcare platform Everside Health Group files for a $100 million IPO

 Everside Health Group, which provides a nationwide in-person and virtual primary health care platform, filed on Friday with the SEC to raise up to $100 million in an initial public offering.


Everside Health is a technology-driven primary care platform that seeks to address the unmet needs of patients, providers, and its clients, which are primarily self-funded employers and labor unions. As of March 31, 2021, it operated 343 centers across over 140 US markets in 33 states and provided care to over 520,000 patients. Its key target markets include state governments, school districts and manufacturers who are typically sensitive to their increasing spend on healthcare claims.

The Denver, CO-based company was founded in 2018 and booked $136 million in sales for the 12 months ended March 31, 2021. It plans to list on the NYSE under the symbol EVSD. Everside Health Group filed confidentially on May 14, 2021. Morgan Stanley, J.P. Morgan, Goldman Sachs, BofA Securities, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.

Wellness company Thorne Healthtech files for a $200 million IPO

 Thorne Healthtech, which offers a suite of personalized dietary supplements, filed on Friday with the SEC to raise up to $200 million.


Thorne Healthtech states that it is a science-driven wellness company pioneering innovative solutions and personalized approaches to health and well-being. Its vertically integrated brands, Thorne and Onegevity, provide actionable insights and personalized data, products, and services. During the past decade, the company has evolved to become a transformative consumer brand, with a base of more than 3 million customers. Thorne employs a go-to-market strategy, combining a direct-to-consumer (DTC) and subscription model with an ecosystem of health professionals. It provides customers with direct access through its mobile, web, and Amazon channels, as well as through a network of more than 42,000 health professionals.

The New York, NY-based company was founded in 1984 and booked $150 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol THRN. Thorne Healthtech filed confidentially on April 19, 2021. BofA Securities, Cowen, Evercore ISI, and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.